Work

Supplementary Data1 from Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2− Metastatic Breast Cancer

Year: 2025

Type: supplementary-materials

Abstract: Supplemental tables and figures

DOI: 10.1158/1078-0432.30029555

Authors: Paula I. Gonzalez-Ericsson, Nisha Unni, Komal Jhaveri, Erica Stringer-Reasor, Qi Liu, Yu Wang, Violeta Sanchez, Guadalupe Garcia, Melinda E. Sanders, Brian D. Lehmann, Justin M. Balko, Ben Park, Brent N. Rexer, Ingrid A. Mayer, Carlos L. Arteaga

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4413906836

Cites:

Cited by:

Related to: 10